The aim of this study was to determine the ability of a disc susceptibility test using 25 faropenem (10-µg) to predict carbapenemase activity in Enterobacteriaceae. A collection 26 of 166 isolates of carbapenemase-producing Enterobacteriaceae (CPE) and 82 isolates of 27
INTRODUCTION 46
Carbapenems are relied upon as one of the few effective options for treatment of 47
Enterobacteriaceae that produce extended-spectrum and/or AmpC β-lactamases. 48
However, their utility is becoming compromised by the increasing occurrence of 49
Enterobacteriaceae that produce carbapenemases (1, 2). Clinical laboratories must have 50 access to simple phenotypic screening tests for the accurate detection of carbapenemase-51 producing Enterobacteriaceae (CPE). A number of tests have been devised for detection 52 of carbapenemases (3) (4) (5) (6) (7) (8) , but these are performed only if there is sufficient suspicion 53 based on the results of antimicrobial susceptibility testing. However, inferring 54 carbapenemase activity from an antibiogram is not always straightforward because some 55 isolates of CPE appear susceptible to carbapenems while isolates without 56 carbapenemases may appear resistant (2). Faropenem medoxomil is an oral penem 57 antibiotic with efficacy for the treatment of community-acquired infections caused by 58
Enterobacteriaceae, including strains with AmpC or extended spectrum ß-lactamases (9). 59
In the first part of this study, we evaluated the effectiveness of disc susceptibility testing 60 with faropenem as a means of predicting carbapenemase activity and compared it with 61 four carbapenems using a collection of 248 Enterobacteriaceae with defined β-62 lactamases. In a second evaluation we examined the utility of the faropenem disc 63 susceptibility test alone to predict carbapenemase activity in 205 consecutive isolates 64 referred to a UK reference laboratory. 65 66 on January 10, 2018 by guest http://jcm.asm.org/ Downloaded from pneumoniae n = 1). Three K1 hyper-producing K. oxytoca were also included as well as a 93 control isolate of E. coli without β-lactamases (NCTC 10418). 94 95 Disc susceptibility testing. Each of the 248 isolates was sub-cultured on to 96 chromID CPS agar (bioMérieux, Basingstoke, UK) and incubated for 18 h in air. 97
Colonies were then suspended in sterile saline (0.85 %) to a density equivalent to 0.5 98
McFarland units using a densitometer (Densimat; bioMérieux). A dipped swab was then 99 used to inoculate a Mueller-Hinton agar plate (Oxoid, Basingstoke, UK). Faropenem 100 powder was kindly supplied by bioMérieux, La Balme-les Grottes, France. Ten 101 milligrams of powder (100 % potency) was dissolved in 10 mL of sterile deionised water 102 and 10 µL of this solution was added to blank paper discs to give a final load of 10-µg 103 faropenem. One of these discs was added to each of the inoculated plates along with the 104 following discs obtained from Oxoid: meropenem (10-µg), doripenem (10-µg), imipenem 105 (10-µg), ertapenem (10-µg) and temocillin (30-µg). Culture plates were incubated for 18 106 h at 37°C in air and zone diameters were recorded. All tests were performed in duplicate 107 on separate occasions. E. coli (NCTC 10418) Isolates were typically referred for investigation of suspected carbapenemase activity or 123 for investigation of an 'unusual' susceptibility pattern. These isolates were subjected to 124 MIC testing using a standard agar dilution methodology (10), with 30 different 125 antimicrobials including 23 β-lactam antibiotics with or without β-lactamase inhibitors. 126
Isolates that showed any evidence of possible carbapenemase activity were further 127 evaluated using molecular assays targeting common carbapenemases (specifically, KPC 128 and OXA-48 non-metallo-enzymes and IMP, NDM and VIM metallo-enzymes). All 129 isolates were also subjected to susceptibility testing with a 10-µg faropenem disc only, 130 using the method described above. E. coli (NCTC 10418) and this corresponded to an inhibition zone diameter of 26 +/-1 mm, which was 148 consistently achieved in every batch of tests using CSLI / EUCAST methodology (11). 149
The average zone diameters for faropenem and four carbapenems against β-lactamase 150 producers are shown in Table 1 . A total of 152/166 isolates of CPE (92%) showed 151 confluent growth up to the edge of the 10-µg faropenem disc (i.e. zone diameter = 6 mm). 152
These included 14/15 isolates that produced KPC and all isolates that produced IMP (n = 153 14), VIM (n = 9) or NDM-1 (n = 115) carbapenemase. Twelve of 13 isolates that 154 produced OXA-48 and one isolate that produced KPC-3 generated a zone of inhibition to 155 faropenem, but with large numbers of colonies inside the zone growing up to the edge of 156 the disc. Only one isolate of CPE (an OXA-48 producer) had a clear zone of inhibition 157 without colonies growing up to the disc when tested against faropenem 10-µg. 158 faropenem discs. All five were Klebsiella pneumoniae and included two ESBL producers 161 (one with CTX-M-3 and one with SHV-11 plus CTX-M-15 plus porin loss) and three 162 isolates with DHA-1 acquired AmpC β-lactamase. The four carbapenems generated mean 163 zone diameters of 10.9 -16.7 mm for CPE (Table 1 ). Figure 1 shows the sensitivity and 164 specificity for all possible zone diameters as a predictor of carbapenemase activity where 165 a zone diameter of ≤'X' mm was used to infer the presence of a carbapenemase. These 166 data show that a zone diameter of 6 mm (i.e. no inhibition) for faropenem predicted 167 carbapenemase activity with a sensitivity of 99% and a specificity of 94%. The next most 168 useful agent was imipenem, where a zone diameter of ≤23 mm as a predictor of 169 carbapenemase activity had a sensitivity of 99% and a specificity of 85%. 170
171
MICs of faropenem were ≥64 mg/liter for all isolates with VIM, IMP and KPC 172 and 99% of isolates with NDM-1 carbapenemase. In contrast, 32 mg/liter was sufficient 173 to inhibit the growth of all but four isolates of non-CPE (range 0.5 -> 64 mg/liter). MICs 174 for isolates with OXA-48 enzyme ranged from 2 -32 mg/liter. A faropenem MIC of ≥16 175 mg/liter was indicative of carbapenemase production with a sensitivity of 96% and a 176 specificity of 91%. 177 178 Fifty-seven isolates of CPE (34%) showed no zone of inhibition when tested 179 against a 30-µg temocillin disc, including all producers (n = 13) of OXA-48 enzyme. 180
One (1.2%) non-CPE isolate (an isolate of K. pneumoniae with CTX-M-3) produced no 181 zone of inhibition to temocillin. Thus, high-level resistance to temocillin has highand was a consistent feature of those producing OXA-48. Figure 2 illustrates carbapenemase producers using molecular methods. A range of species were found with 189
C. freundii (n = 1) and Kluyvera ascorbata (n = 1). Table 2 shows the enzyme types that 192 were encountered and the presumptive phenotype of all other isolates for which there was 193 no evidence of carbapenemase activity. The presumptive phenotype of non-194 carbapenemase producers was derived from analysis of the antibiogram. Table 2 Enterobacteriaceae with inhibition zone diameters of <23 mm for imipenem or <25 mm 235 for ertapenem or meropenem. Applying these criteria to our collection of 248 236
Enterobacteriaceae resulted in a sensitivity and specificity of 99% and 69% for 237 ertapenem, 98% and 88% for imipenem, 99% and 79% for meropenem, respectively. The 238 faropenem disc test therefore showed an equivalent sensitivity (99%) and superior 239 specificity (94%) than any of these recommended screening indicators of potential 240 carbapenemase activity. When applied to 205 consecutive isolates referred to a UK 241 reference laboratory, the test retained good sensitivity (98%) but lower specificity (87%). 242
This lower specificity is perhaps not surprising as the reference laboratory often receives 243 atypical isolates and the information accompanying 85 of these isolates mentioned an 244 'unusual' antibiogram among the reasons for referring the isolate. faropenem, all had a zone of inhibition to a faropenem 10-µg disc (range 8-13 mm). 257
258
We conclude that inclusion of a faropenem 10-µg disc in routine susceptibility 259 tests provides an excellent screening test for presumptive detection of Enterobacteriaceae 260 that produce carbapenemases. It is possible that the local prevalence of particular β-261 lactamase producers may impact on the value of the test, for example 3/5 isolates that 262 produced DHA-1 enzyme gave no zone of inhibition to faropenem and would be 263 regarded as presumptive carbapenemase producers. It would therefore be very useful for 264 this test to be validated with other collections of Enterobacteriaceae in different countries 265 to further establish its utility. As faropenem is effectively hydrolyzed by carbapenemases 266 it may also be a useful substrate for inclusion in a variety of other assay formats for rapid 267 phenotypic detection of carbapenemases and differentiation from other types of β-268 lactamase (3, 4, 6, 7, 20) . 
